FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer By Ogkologos - April 8, 2026 145 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR 31-Year-Old Mother Dies of Cancer After Her Chemotherapy Was Paused During... October 19, 2020 FDA Approves New and Updated Indications for Temozolomide Under Project Renewal October 3, 2023 How People With Cancer Can Benefit From Online Therapy October 22, 2020 Modest Effectiveness of Screening Colonoscopy for the Prevention of Colorectal Cancer... October 10, 2022 Load more HOT NEWS FDA Approves Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable NSCLC Struggling Waitress Who Can’t Feed Her 4 Kids After Husband’s Cancer... 6 Things That Helped Me Think Positively During Cancer: A Patient... Deputy Spends His Days Off Teaching Life Skills To Young Boys...
